Cordis Corporation Announces Broad Range of Clinical Studies and Events for the CYPHER® Sirolimus-eluting Coronary Stent at TCT 2005
MIAMI, Oct. 14 -- Cordis Corporation today
announced the schedule of key clinical presentations focusing on the safety
and efficacy of the CYPHER® Sirolimus-eluting Coronary Stent in patients
with complex coronary lesions. The new data will be presented at the
Transcatheter Cardiovascular Therapeutics (TCT 2005) Scientific Symposium in
Washington, D.C. on October 16 - 21.
Presentations include results from two new randomized studies: the SISR
trial, which evaluated the CYPHER® Stent versus brachytherapy in patients
with in-stent restenosis (reblockage) of a previously stented artery, and the
PRISON II study, examining the CYPHER® Stent versus bare metal stents in
patients with complete obstructions of the coronary artery (chronic total
occlusions). Other noteworthy presentations include a new meta-analysis of
CYPHER® Stent versus Taxus Stent clinical trials; a detailed analysis of the
cost-effectiveness of the CYPHER® Stent versus coronary artery bypass
grafting (CABG) from the ARTS I and ARTS II data; along with results from the
SIRIUS 2.25 mm trial.
"The studies that will be presented at this year's meeting will continue
to add to the significant body of scientific evidence for the CYPHER® Stent
across a broad spectrum of patients with complex coronary artery disease,"
said Dennis Donohoe, MD, Worldwide Vice President of Clinical Research and
Regulatory Affairs, Cordis Corporation.
TCT 2005 presentations:
The SISR trial
Nine-month results from the multi-center prospective,
randomized comparison of the CYPHER® Stent versus radiation from within a
vessel (brachytherapy) in patients with in-stent restenosis. David Holmes,
M.D. will present the data on Monday, October 17 at 11:45 a.m. in a plenary
session.
The PRISON II trial
Results from a prospective, randomized trial of the
CYPHER® Stent and bare metal stents in patients with chronic total
occlusions. Maarten Suttorp, M.D. will present the data on Tuesday, October 18
at 11:00 a.m.
The Drug-Eluting Summit
New data on drug-eluting stents will be
featured in this session scheduled for Thursday, October 20.
CYPHER® Stent
Overlapping Stent Data, 9:23 a.m.: Campbell Rogers, M.D. will review the safety
and efficacy of overlapping stents from
randomized clinical trials.
- CYPHER® Stent vs. Taxus Stent Meta Analysis, 10:28 a.m.: Stephan
Windecker, M.D. will present new results from an independently based
meta-analysis of head-to-head clinical trials for the CYPHER® Stent
vs. Taxus Stent.
- ARTS II Cost-effectiveness Analysis, 11:50 a.m.: David Cohen, M.D.
will provide a clinical trial update on the cost-effectiveness of the
CYPHER® Stent in treating multi-vessel disease. This update will
include insights from the ARTS I and ARTS II studies, which evaluated
the most complex patient population to be studied involving drug-
eluting stents.
- Featured Lecture, 1:32 p.m.: Donald Baim, M.D. and Jeffrey Moses,
M.D. will present the six-month results from the SIRIUS 2.25 mm small
vessel study.
Sponsored events:
- Cordis Corporation Evening Symposium (CME Program): "The Growing Body
of Drug-Eluting Stent Data: Clinical Trials and Real-World Results",
October 17th from 7 p.m. - 10 p.m. at the Grand Hyatt Washington,
Independence Ballroom, 1000 H Street, NW. Event chair: David R.
Holmes, Jr., MD.
- Cordis Corporation Breakfast Symposium (CME Program) - "Dealing with
the Difficult: Case Study Reviews of Complicated DES", October 20th
from 7 a.m. - 8 a.m. at the Washington Convention Center: Room 154 AB.
Event chair: David G. Rizik, MD
More information on the data to be presented on the CYPHER® Stent at TCT
2005 can be found online at http://www.tctmd.com .
About the CYPHER® Stent
The CYPHER® Stent has been chosen by cardiologists
worldwide to treat more than 1.5 million patients with coronary artery disease.
The safety and
efficacy of the device is supported by a robust clinical trial program that
includes more than 40 studies, inclusive of independent clinical trials, that
examine the performance of the CYPHER® Stent in a broad range of patients.
Developed and manufactured by Cordis Corporation, the CYPHER® Stent is
currently available in more than 80 countries and has the longest-term
clinical follow-up of any drug-eluting stent. The CYPHER SELECT(TM)
Sirolimus-eluting Coronary Stent, which is the first next generation drug-
eluting stent, was launched in Europe, Asia Pacific, Latin America and Canada
in 2003. More information about the CYPHER® Stent can be found at
http://www.cypherusa.com .
About Cordis Corporation
Cordis Corporation, a Johnson & Johnson company,
is a worldwide leader in developing and manufacturing interventional vascular
technology. Through the
company's innovation, research and development, physicians worldwide are
better able to treat the millions of patients who suffer from vascular
disease.
SOURCE Cordis Corporation |
